MDM2 overexpression
|
GIST
|
MDM2 overexpression
|
GIST
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
MDM2 overexpression
|
Liposarcoma
|
MDM2 overexpression
|
Liposarcoma
|
erdafitinib + RO5503781 Sensitive: D – Preclinical
|
erdafitinib + RO5503781 Sensitive: D – Preclinical
|